Ceraso A, Lin JJ, Schneider-Thoma J, Siafis S, Tardy M, Komossa K, et al. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev 2020;8:CD008016. https://www.ncbi.nlm.nih.gov/pubmed/32840872
Findling RL, Cavus I, Pappadopulos E, Vanderburg DG, Schwartz JH, Gundapaneni BK, et al. Ziprasidone in adolescents with schizophrenia: results from a placebo-controlled efficacy and long-term open-extension study. J Child Adolesc Psychopharmacol 2013;23(8):531–44. https://www.ncbi.nlm.nih.gov/pubmed/24111983
Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry 2016;50(5):410–72. https://www.ncbi.nlm.nih.gov/pubmed/27106681
Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia. Part 3: Update 2015 management of special circumstances: Depression, suicidality, substance use disorders and pregnancy and lactation. World J Biol Psychiatry 2015;16(3):142–70. https://www.ncbi.nlm.nih.gov/pubmed/25822804
Hor K, Taylor M. Suicide and schizophrenia: a systematic review of rates and risk factors. J Psychopharmacol 2010;24(4 Suppl):81–90. https://www.ncbi.nlm.nih.gov/pubmed/20923923
Krause M, Zhu Y, Huhn M, Schneider-Thoma J, Bighelli I, Chaimani A, et al. Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: A network meta-analysis. Eur Neuropsychopharmacol 2018;28(6):659–74. https://www.ncbi.nlm.nih.gov/pubmed/29802039
Lambert TJ, Reavley NJ, Jorm AF, Oakley Browne MA. Royal Australian and New Zealand College of Psychiatrists expert consensus statement for the treatment, management and monitoring of the physical health of people with an enduring psychotic illness. Aust N Z J Psychiatry 2017;51(4):322–37. https://www.ncbi.nlm.nih.gov/pubmed/28343435
McAllister-Williams RH, Baldwin DS, Cantwell R, Easter A, Gilvarry E, Glover V, et al. British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017. J Psychopharmacol 2017;31(5):519–52. https://www.ncbi.nlm.nih.gov/pubmed/28440103
Shimomura Y, Kikuchi Y, Suzuki T, Uchida H, Mimura M, Takeuchi H. Antipsychotic treatment in the maintenance phase of schizophrenia: An updated systematic review of the guidelines and algorithms. Schizophr Res 2020;215:8–16. https://www.ncbi.nlm.nih.gov/pubmed/31784340
Ten Velden Hegelstad W, Haahr U, Larsen TK, Auestad B, Barder H, Evensen J, et al. Early detection, early symptom progression and symptomatic remission after ten years in a first episode of psychosis study. Schizophr Res 2013;143(2-3):337–43. https://www.ncbi.nlm.nih.gov/pubmed/23219862
Tiihonen J, Tanskanen A, Taipale H. 20-year nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode schizophrenia. Am J Psychiatry 2018;175(8):765–73. https://www.ncbi.nlm.nih.gov/pubmed/29621900
Whitworth AB. Psychopharmacological treatment of schizophrenia during pregnancy and lactation. Curr Opin Psychiatry 2017;30(3):184–90. https://www.ncbi.nlm.nih.gov/pubmed/28306564
Zipursky RB, Menezes NM, Streiner DL. Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review. Schizophr Res 2014;152(2-3):408–14. https://www.ncbi.nlm.nih.gov/pubmed/23972821